Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK announced that its drug Jemperli (dostarlimab) has received the US FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, based on data showing a 100% complete clinical response in a trial of 42 patients. This designation may expedite the drug’s development and review, potentially shifting the treatment paradigm for this cancer type, which currently involves significant quality-of-life impacts from standard care procedures. The ongoing AZUR-1 trial seeks to confirm these promising results, highlighting a possible substantial advancement in therapy options for patients.
More about GlaxoSmithKline
GSK is a global biopharma company focused on uniting science, technology, and talent to combat diseases, with a particular emphasis on oncology, including immuno-oncology and tumor-cell targeting therapies. Their research and development efforts are directed towards maximizing patient survival, particularly in hematologic malignancies, gynecologic cancers, and other solid tumors.
YTD Price Performance: -4.72%
Average Trading Volume: 8,861,590
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £54.25B
See more data about GSK stock on TipRanks’ Stock Analysis page.
